Welcome to our dedicated page for Electrocore news (Ticker: ECOR), a resource for investors and traders seeking the latest updates and insights on Electrocore stock.
electroCore, Inc. reports developments in bioelectronic medicine and wellness products built around non-invasive vagus nerve stimulation, or nVNS. Company news commonly covers prescription gammaCore for migraine, Quell Fibromyalgia, Truvaga and Truvaga Plus consumer wellness products, and TAC-STIM for human performance.
Recurring updates include financial results, U.S. prescription sales activity, direct-to-consumer wellness sales, product-line commercialization, clinical research involving gammaCore nVNS, and participation in healthcare and investor conferences. News also highlights applications of vagus nerve stimulation across prescription medical uses and consumer wellness settings.
electroCore (Nasdaq: ECOR) announced publication in JAMA Network Open of a cluster randomized clinical trial evaluating a modified Quell device added to outpatient physical therapy for fibromyalgia.
Among 384 participants, PT-Quell showed greater pain and fatigue improvements, with benefits seen by 30 days and lasting up to six months.
electroCore (NASDAQ: ECOR) will present at the LD Micro Invitational XVI conference in Los Angeles on May 18, 2026. Interim President and CFO Joshua Lev will deliver the company presentation at 10:30 am PT and hold one-on-one investor meetings; a webcast is available.
electroCore (Nasdaq: ECOR) reported Q1 2026 net sales of $9.6 million, up ~43% year‑over‑year, with 87% gross margin and GAAP net loss of $5.3 million. Adjusted EBITDA net loss improved 24% to $2.3 million. The VA remained the largest channel; Quell and Truvaga contributed growth. The company reaffirmed ~30% full‑year 2026 revenue growth guidance and reported cash and marketable securities of $8.8 million at March 31, 2026.
electroCore (Nasdaq: ECOR) announced on April 30, 2026 that TAC-STIM, its handheld non-invasive vagus nerve stimulation wellness product for human performance, was named a national semifinalist in the National Safety Council 2026 Work to Zero Safety Innovation Challenge.
TAC-STIM, developed with the U.S. Air Force Research Laboratory, is deployed across multiple U.S. military commands and will be presented at the NSC Safety Summit on May 7–8, 2026; semifinalists may access the Work to Zero Pilot Grant Program.
electroCore (Nasdaq: ECOR) will report first-quarter financial results for the period ended March 31, 2026, after market close on Wednesday, May 6, 2026.
Management will host a webinar at 4:30 PM EDT to review results and answer questions; investors may join by dial-in or registration (webinar ID and passcode provided).
electroCore (Nasdaq: ECOR) announced it will present at the Market Movers Investor Summit on May 5, 2026. Joshua Lev, Interim President and CFO, will deliver a company presentation at 12:20 PM ET and hold one-on-one meetings at the Bank of New York, 48 Wall Street, New York.
Requests for invitations are available at www.marketmoverssummit.com. The summit features presentations, fireside chats, one-on-ones, and networking across May 4–5, 2026.
electroCore (Nasdaq: ECOR) is featured in the documentary Hacking the Vagus Nerve, part of the Healing Journeys series, highlighting clinical and consumer uses of non-invasive vagus nerve stimulation (nVNS).
The film includes expert commentary from Dr. Peter S. Staats and showcases electroCore products: prescription gammaCore, Truvaga Plus, and TAC-STIM, and discusses ongoing work in PTSD, Long COVID, and stress-related conditions. The documentary is available at the Healing Journeys website.
electroCore (Nasdaq: ECOR) will participate in the 25th Annual Needham Virtual Healthcare Conference on April 15, 2026. Management presentation is scheduled for 2:15 pm ET, led by Joshua Lev, Interim President and Chief Financial Officer.
Investors can request one-on-one meetings via their Needham representative or by emailing investors@electrocore.com.
electroCore (Nasdaq: ECOR) announced enrollment of the first eight patients in an investigator-led study evaluating gammaCore non-invasive vagus nerve stimulation (nVNS) as an adjunctive treatment for PTSD.
The study will enroll up to 40 adults, assess outcomes over a 12-week treatment period, and run approximately 10 months. Primary endpoints are treatment-related serious adverse events and change in CAPS-5 total score at 12 weeks. electroCore is providing an educational grant and devices.
electroCore (Nasdaq: ECOR) announced on April 1, 2026 the publication of a Frontiers in Neuroscience paper reporting a post-hoc analysis of 35 patients with chronic mild traumatic brain injury (mTBI) and comorbid PTSD. The analysis found adjunctive non-invasive vagus nerve stimulation (nVNS) significantly reduced overall symptom burden across cognitive, affective, and somatic domains.
According to the company, the study examined a high-symptom-burden cohort and adds to evidence supporting the therapeutic potential of nVNS for chronic mTBI with PTSD.